Novartis AG
NVS · NYSE
NVS · NYSE
Novartis is a pharmaceutical company that earns revenue by selling medicines. Its reported third-quarter 2026 net sales were USD 14.5 billion, up 4% year over year in both constant currencies and U.S. dollars. The supplied evidence highlights Kisqali, Kesimpta and Scemblix as important growth medicines, with their sales helping offset generic competition. Novartis also has the investigational drug MRT-6160 in Phase 2 testing for moderate-to-severe psoriatic arthritis. The evidence does not give a segment breakdown, customer breakdown or individual product contributions, so the relative size of those businesses cannot be established from these figures.
NVS gained 3.09% over the stated comparison, from $156.27 to $161.10. The stock had fallen to $151.12 on October 23, then rebounded during the week beginning October 26, closing at $153.81 on Monday and $156.86 on Tuesday. Novartis reported third-quarter results on Tuesday: sales rose 4% year over year, key-drug demand supported growth, and the company raised its full-year core operating income outlook while backing its sales outlook. Those positives came alongside missed revenue expectations and steep declines in reported operating and net income, which the company attributed in part to impairment and higher expenses. Shares eased slightly Wednesday, then rose to $161.10 Thursday, extending the rebound after the results.
NVS rose 4.42% over the reported interval, from $143.84 to $150.20. The move was not a straight climb: shares fell to $142.41 on October 13, then rebounded to $146.88 on October 14 and $150.38 on October 15, before edging up to $150.62 on October 16 and slipping to $150.20 on October 19. The supplied evidence does not identify company-specific news behind the advance or the late pullback. It also provides no benchmark or market-sector performance with which to attribute the move to broader trading conditions, so the weekly gain is clear but its catalyst is not.
Novartis gained 2.06% over the reported week, rising from $140.93 on October 5 to $143.84 on October 12. Shares dipped slightly to $140.79 on October 6, then advanced to $143.28 on October 7, eased to $143.11 the following day, and continued higher through October 12. The supplied evidence does not establish a company-specific event as the driver of those daily moves: a Seeking Alpha headline reports a halt to a mid-stage trial of kidney drug Fabhalta, but provides no publication date or trading-day link. Nor does the evidence provide broader market context to explain the rise, so the week’s gain cannot be attributed more specifically.
Novartis fell 3.38%, from $145.71 to $140.79. The decline was concentrated early in the period: the shares closed at $142.57 on September 30 and $141.05 on October 1, then changed little over the next three sessions, ending at $140.79 on October 6. The supplied evidence does not establish a company-specific catalyst for that sequence. Zacks reported that Novartis obtained global rights to Abogen’s ABO2203 in a deal valued at $7.8 billion, but the snippet does not give the announcement date, so it cannot be tied to the week’s trading. A Benzinga headline says the stock traded higher on a particular day, but its snippet does not identify the date or explain the move. No market benchmark is provided to assess broader-market context.
Novartis fell 1.76%, from $143.57 to $141.05, over the week. Shares rose to $146.88 on Monday, then declined on each of the next three sessions, giving back the entire early-week advance and finishing below the prior Thursday’s close. The sharpest daily drop was Wednesday, when the stock fell to $142.57 on the week’s highest reported volume of 3.06 million shares; it slipped a further 1.07% on Thursday. Novartis announced a licensing and option agreement with China-based Abogen Biosciences to develop mRNA-encoded therapies, including an exclusive worldwide licence to lead asset ABO2203. The supplied evidence does not connect that announcement to the share-price moves, and provides no market benchmark for comparison.
NVS rose 2.89%, from $138.70 to $142.71, across the supplied period. It advanced from $140.98 on September 21 to $141.28 on September 22, then added more on September 23, closing at the period high of $142.71; the supplied daily closes show no material reversal during those sessions. Company-specific coverage offered two supportive developments: a positive CHMP opinion for Cosentyx in polymyalgia rheumatica and a radioligand-therapy licensing deal with BoomRay, whose potential value is up to $900 million. Against those positives, coverage also highlighted clinical and pipeline setbacks and shareholder pressure for board changes. The evidence provides no dated event sequence or market benchmark, so it cannot establish which news drove the daily gains or quantify market effects.
Novartis fell 9.44% over the week, from $152.06 to $137.70, as two clinical-trial failures in one week overwhelmed an earlier rally. The stock climbed from $152.06 on August 31 to $163.09 on September 3, then eased to $159.99 on September 4 before plunging 13.94% on September 8 on volume of 10.3 million shares. Coverage tied the selloff to the second trial failure and concerns that the setback could weaken confidence in Novartis’s pipeline and the broader cholesterol-drug class. The decline was compounded by reports that a major investor is seeking stronger acquisition oversight or a board overhaul after roughly $30 billion of recent deal activity.
Novartis rose 5.46%, or $8.44, from $154.65 to $163.09 over the measured week. The stock first fell 1.14% to $152.06 on Monday, then surged 6.04% on Tuesday on positive Phase 3 REMODEL-1 and REMODEL-2 results for oral multiple-sclerosis drug remibrutinib; trading volume also more than tripled to 4.33 million shares. The data showed remibrutinib reduced relapse rates versus Aubagio and supported potential global regulatory filings, making it the dominant catalyst. Shares extended the move on Wednesday and Thursday, rising to $162.46 and $163.09, respectively. Coverage of a potential $3.2 billion Alteogen drug-delivery agreement provided an additional strategic positive, while no material reversal followed Tuesday's advance.
Novartis fell $1.59, or 1.02%, over the week, from $156.24 to $154.65. The stock first gained $2.62 on Aug. 21, then slipped $0.84 on Aug. 24 before adding $1.96 on Aug. 25. It reversed sharply thereafter, dropping $2.44 on Aug. 26 and another $2.89 on Aug. 27, giving back all of Tuesday’s gain and finishing below the prior week’s close. The supplied evidence identifies no Novartis-specific announcement, earnings release, guidance change, or analyst action to explain the decline. Trading therefore appears to have reflected broader market or healthcare-sector factors, although the evidence does not provide a specific market catalyst.
Novartis rose 2.98% over the week, from $151.72 to $156.24. The main move came Wednesday, when the stock jumped 3.82% to $160.31 on 2.4 million shares, although the supplied evidence does not identify a company-specific catalyst behind that advance. It gained 0.72% Monday and another 1.70% Tuesday, extending the prior close’s recovery from $150.88. Thursday then reversed part of the rally, with the stock falling 2.54% to $156.24 and giving back more than half of Wednesday’s gain. Available coverage characterized the shares as range-bound or consolidating, so the week appears to have been driven primarily by trading momentum rather than reported financial results or disclosed corporate news.
Novartis rose $3.12, or 2.03%, over the supplied week, from $153.67 to $156.79. The stock initially slipped to $153.27 on August 4 before recovering to $154.44 on August 5 and easing marginally on August 6. The largest move came on August 7, when shares climbed to $156.33, followed by a smaller gain on August 10. No company-specific announcement, financial release, contract, or management commentary was supplied to explain the advance. Reported positioning signals were mixed: Mirae Asset and SOA Wealth Advisors bought shares, while Boston Common and Triasima reduced holdings; an ETF-channel report also cited NVS among notable outflows. The evidence therefore points to trading and ownership-flow factors rather than a confirmed fundamental catalyst.
Novartis fell 4.12%, from $159.85 to $153.27 over the reported period. The decline accelerated late in the sequence: shares slipped from $159.85 to $158.44 through July 30, dropped to $156.15 on July 31, then fell another 1.59% on August 3 and 0.26% on August 4. Novartis announced FDA approval of a Pluvicto combination for PSMA-positive metastatic hormone-sensitive prostate cancer, a potentially supportive regulatory development, but the evidence does not show that it changed trading. Commentary also describes the company as managing major patent cliffs. No financial results or market-wide driver is supplied, so the stock appears to have moved lower without an evidence-backed explanation for the weekly selloff.
